Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for rare bleeding disorder: coagadex trial targets AL amyloidosis complications

NCT ID NCT06963216

First seen Feb 02, 2026 · Last updated May 20, 2026 · Updated 17 times

Summary

This study tests a drug called Coagadex in 15 adults with acquired factor X deficiency caused by AL amyloidosis. The goal is to see if it safely stops bleeding episodes and helps manage bleeding during surgery. Participants receive the drug and are monitored for response over 72 hours and beyond.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACQUIRED FACTOR X DEFICIENCY are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cancer Clinical Trials Unit

    RECRUITING

    London, London, NW1 2PG, United Kingdom

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Mayo Clinic Arizona

    RECRUITING

    Phoenix, Arizona, 85054, United States

    Contact

  • Mayo Clinic Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.